A lab at the Childrens Cancer Research Institute in Vienna, in collaboration with a network of European oncologists, had developed an anti-GD2 mAb that it made in CHO cells, and by 2011, it was in Phase III clinical trials, and the institute licensed its rights to Apeiron, a local biotech company.The FDA approved United Therapeutics application in March 2015, as did the European Medicines Agency.In 2017, United Therapeutics withdrew the European marketing authorization, and said that it was having trouble making enough of the drug to sell in Europe.In October 2016, Apeiron licensed the rights to Ch14.18 to the UK biotech company, EUSA, and in May 2017, Apeiron and EUSA obtained EMA approval to market Ch14.18, by then called dinutuximab beta. References
External links
"Dinutuximab". Drug Information Portal. U.S. National Library of Medicine. "Dinutuximab beta". Drug Information Portal. U.S. National Library of Medicine.
Warnings
Mobocertinib may increase the chance of QTC prolongation, specifically Torsades de Pointes which can be fatal. Adverse Effects
More serious side effects of Mobocertinib may include agitation, bloating of the eyes, lips, feet, blurred vision, coma, decreased urine output, headache, hostility, diarrhea, depression, dizziness, fainting, lethargy, anxiety, nausea, seizures, weight gain, fatigue as well as edema. Other side effects which may be less frequent are: chills, cough, dilated neck veins, ill-feeling and trouble with breathing. Other notable side effects of taking Mobocertinib are: having an acidic stomach, heartburn, acidity, hair loss/thinning, bone pain, sore throat, stuffy nose, trouble swallowing, vomiting and weakness in hands and feet. History
Mobocertinib was studied in participants with previously treated metastatic non-small cell lung cancer with EGFR exon 20 insertions. References
External links
"Mobocertinib". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT02716116 for "A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer" at ClinicalTrials.gov